Information  X 
Enter a valid email address

SEGRO PLC (SGRO)

  Print      Mail a friend       Annual reports

Thursday 09 April, 2020

SEGRO PLC

Director/PDMR Shareholding

RNS Number : 3473J
SEGRO PLC
09 April 2020
 

9 April 2020

SEGRO plc (the Company)

Dealing by Director

On 9 April 2020 , the Company was notified of the following transaction by a Director. Following the transaction, the Director's beneficial holding is as follows:

Director

Date of purchase

Number of shares purchased

Purchase price per share

(pence)

Resultant beneficial holding

Mary Barnard

7 April 2020

1,746

798.49

7,408

 

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation (2014/596/EU) in relation to the transaction listed above is set out below:

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Mary Barnard

2.

Reason for the notification

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

SEGRO plc

b)

 

LEI

213800XC35KGM9NFC641

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 10 pence each

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

Total

£7.9849

1,746

£13,941.64

d)

 

Aggregated information

N/A

e)

 

Date of the transaction

 

 

7 April 2020

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

 

Stephanie Murton

Legal Counsel

020 7451 9083


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDKLBBBZLZBBK

a d v e r t i s e m e n t